olorofim

11/01/2023 - "Refractory Microascus Bronchopulmonary Infection Treated with Olorofim, France."
01/01/2018 - "F901318 is a potential new agent for the treatment of invasive infections caused by A flavus with PDs that are comparable with other first-line triazole agents."
01/01/2019 - "We studied the in vivo efficacy of olorofim intraperitoneal therapy (15 mg/kg of body weight every 8 h for 9 days) against infection with A. "
01/01/2021 - "Olorofim therapy significantly improved survival compared to that of the untreated controls; 80%, 100%, and 100% of treated mice survived infection by Scedosporium apiospermum, Pseudallescheria boydii, and Lomentospora prolificans, respectively, while less than 20% of the control mice (phosphate-buffered saline [PBS] treated) survived at 10 days postinfection. "
11/01/2019 - "Luliconazole and olorofim show promise for treating azole-resistant infections caused by these cryptic species."

11/01/2018 - "In vivo data showed that olorofim was highly efficacious in prolonging survival of mice with disseminated aspergillosis due to A. "
11/01/2018 - "The in vivo efficacy of olorofim was determined in an immunosuppressed murine model of disseminated aspergillosis. "
11/08/2016 - "In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. "
01/01/2019 - "Furthermore, the efficacy of olorofim was unrelated to the triazole MICs of the infecting Aspergillus spp. These results show olorofim to be a promising therapeutic agent for invasive aspergillosis."
01/01/2018 - "Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus."

01/01/2021 - "Cyclophosphamide-immunosuppressed CD-1 mice infected by Scedosporium apiospermum, Pseudallescheria boydii (Scedosporium boydii), and Lomentospora prolificans were treated by intraperitoneal administration of olorofim (15 mg/kg of body weight every 8 h for 9 days). "
01/01/2019 - "We studied the in vivo efficacy of olorofim intraperitoneal therapy (15 mg/kg of body weight every 8 h for 9 days) against infection with A. "

01/01/2021 - "In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis."
01/01/2021 - "These results indicate olorofim to be a promising therapeutic agent for systemic scedosporiosis/lomentosporiosis, devastating emerging fungal infections that are difficult to treat with currently available antifungals."
01/01/2021 - "We studied the in vivo efficacy of a new fungicidal agent, olorofim (formerly F901318), against scedosporiosis and lomentosporiosis in neutropenic animals. "
01/01/2023 - "In conclusion, alexidine, amorolfine and olorofim were identified as promising compounds to be studied against scedosporiosis and lomentosporiosis."

01/01/2023 - "Prolonged Remission of Azole-Resistant Lung Aspergillosis with Olorofim, in an Adolescent with X-Linked Chronic Granulomatous Disease."